A healthy colon is packed with bacteria that starve out C. difficile and keep its spores from waking up. Broad-spectrum antibiotics flatten that community; the drugs used to treat C. diff itself, vancomycin and fidaxomicin, finish the job. When the course ends, leftover spores recolonize an empty colon, the diarrhea returns, and another course of antibiotics locks the cycle in tighter 1. The live biotherapeutics deliver the missing community back: Rebyota as a donor-stool slurry, Vowst as the spore-only fraction left after an ethanol wash 2 3.
The numbers hold across trials. In Vowst's pivotal trial, recurrence at eight weeks was 12.4% versus 39.8% on placebo 4. Pooled across its phase 3 studies, about 9 in 10 stayed clear at eight weeks and roughly 85 in 100 held through six months 5. Rebyota lands in the same range 6. Older fecal transplant does too, at around 80 to 85 percent per procedure 7, so the 2024 guideline puts all three on the table for two-or-more recurrences 8.
This is a prescription decision, so bring it to the clinician yourself.
The arc after a working treatment:
The fine print — when to skip it, and what people get wrong
- "It treats the infection." No. It only prevents recurrence; antibiotics still clear the active episode first.
- "It's a fancy probiotic." No. Over-the-counter probiotics don't prevent recurrent C. diff; these are screened donor-stool biologics.
Made from human donor stool: donors are screened, but the label warns of residual infection risk, traced to a 2019 case under looser rules 9. Severe immunosuppression and pregnancy were trial-excluded and need a specialist's call.
- 1Guh et al. (2020). Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. New England Journal of Medicine. link
- 2FDA (2022). FDA Approves First Fecal Microbiota Product (Rebyota). link
- 3FDA (2023). FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection (Vowst). link
- 4Feuerstadt et al. (2022). SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. New England Journal of Medicine. link
- 5Khanna et al. (2024). Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection. Therapeutic Advances in Gastroenterology. link
- 6Khanna et al. (2022). Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs. link
- 7Quraishi et al. (2017). Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary Pharmacology & Therapeutics. link
- 8Peery et al. (2024). AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. link
- 9FDA (2020). Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms. link
დაკავშირებული სახელმძღვანელოში (5)
- — Broad antibiotics like the fluoroquinolones are a leading trigger for the C. diff cycle these drugs exist to break. Skipping a needless course is prevention.
- — FMT and these newer FDA-approved live biotherapeutics are the same idea; the products are the regulated version.
- — Repeated antibiotic courses are how people end up in the C. diff relapse cycle these products are built to break.
- — If diarrhoea won't quit, recurrent C. diff is one treatable cause — and re-seeding the gut ends the loop in nine of ten.
- — Ordinary probiotics won't fix recurrent C. diff — these are the heavy-duty, whole-community version that does.
Microbiome Drugs for C. diff
Single in-clinic enema (Rebyota) or four oral capsules daily for three days with one bowel-prep evening (Vowst). No ongoing protocol.
For the rCDI patient, breaking the relapsing-diarrhea cycle restores daily function within 1–2 weeks. ECOSPOR III absolute risk reduction 27 percentage points at 8 weeks (Feuerstadt et al., NEJM 2022); PUNCH CD3 showed ~12 percentage points (Khanna et al., Drugs 2022); ~85–92% sustained response at 6 months in pooled analyses.
One pivotal Phase 3 RCT per product (PUNCH CD3 for Rebyota, ECOSPOR III for Vowst), supportive open-label Phase 3 (ECOSPOR IV), integrated analyses across trials, AGA 2024 GRADE-based guideline recommendation (Peery et al., Gastroenterology 2024). Not a 5: no head-to-head against FMT or each other, and the Bayesian primary analysis design of PUNCH CD3 is non-standard.
Active rCDI involves ≥10 watery stools/day, dehydration, malabsorption — energy crash is severe. Real-world Rebyota cohorts show quality-of-life and functional recovery to near-baseline within 4–8 weeks of successful treatment.
rCDI carries non-trivial mortality (tens of thousands of US deaths/year; Guh et al., NEJM 2020) and successful microbiome restoration reduces hospitalization and death risk in this subgroup. Population-bounded — at-risk pool is adults with prior rCDI, not the general population — so the effect on overall life expectancy is small but real.
Breaking a months-to-years cycle of relapsing infection produces real anxiety and depression relief; rCDI QoL data shows baseline psychological burden comparable to active IBD, with measurable improvement after sustained response.
Wholesale acquisition cost ~$9,500/course Rebyota, ~$17,500/course Vowst. Most commercially-insured and Medicare patients pay little or nothing after coverage and copay programs (Vowst Voyage to $0 for eligible commercial patients), but the listed cost is in the major tier and uninsured access depends on manufacturer assistance.